Downregulation of hsa-miR-4328 and target gene prediction in Acute Promyelocytic Leukemia
References
- 1. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11(123). DOI: 10.1038/s41408-021-00514-3824549434193815
- 2. Cicconi L, Testi AM, Montesinos P, Rego E, Zhu HH, Takahashi H, et al. Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer J. 2021;11(10):14-7. DOI: 10.1038/s41408-021-00561-w852053234657125
- 3. Zhang X, Sun J, Yu W, Jin J. Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomark Res. 2021;9(1):1-15. DOI: 10.1186/s40364-021-00284-x810113633957999
- 4. Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet? Hematol Oncol Clin North Am. 2011;25(6):1215-33. DOI: 10.1016/j. hoc.2011.10.002
- 5. Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019;60(13):3107-15. DOI: 10.1080/10428194.2019.1613540747963331842650
- 6. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgrd L, et al. Continuing high early death rate in acute promyelocytic leukemia: A population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-34. DOI: 10.1038/leu.2011.7821502956
- 7. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012;26(8):1743-51. DOI: 10.1038/leu.2012.5722422168
- 8. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.02816989803
- 9. Ehtesham N, Sharifi M. From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia. Adv Biomed Res. 2016;5(1):187. DOI: 10.4103/2277-9175.190996515697528028527
- 10. Nervi C, Fazi F, Rosa A, Fatica A, Bozzoni I. Emerging role for microRNAs in acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:73-84. DOI: 10.1007/978-3-540-34594-7_517217039
- 11. Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019;12(1):1-20. DOI: 10.1186/s13045-019-0734-5653490131126316
- 12. Ismail I, Sulong S, Hassan R. MicroRNAs as Potential Biomarkers in Acute Promyelocytic Leukaemia. New J Sci. 2014;2014:1-6. DOI: 10.1155/2014/932342
- 13. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene. 2009;28(45):4034-40. DOI: 10.1038/onc.2009.25519749800
- 14. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):1-9. DOI: 10.1093/nar/gni178129299516314309
- 15. Lee K, Kang JH, Kim HM, Ahn J, Lim H, Lee JJ, et al. Direct electrophoretic microRNA preparation from clinical samples using nanofilter membrane. Nano Converg. 2020;7(1):1-11. DOI: 10.1186/s40580-019-0212-3695538531930443
- 16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-8. DOI: 10.1038/nprot.2008.7318546601
- 17. Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top Microbiol Immunol. 2007;313:85-100. DOI: 10.1007/978-3-540-34594-7_617217040
- 18. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, et al. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Mol Oncol. 2019;13(10):2278-96. DOI: 10.1002/1878-0261.12561676378031402562
- 19. Hummel R, Wang T, Watson DI, Michael MZ, Van Der Hoek M, Haier J, et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep. 2011;26(4):1011-7. DOI: 10.3892/or.2011.138121743970
- 20. Rooda I, Hensen K, Kaselt B, Kasvandik S, Pook M, Kurg A, et al. Target prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cells. Sci Rep. 2020;10(1):1-13. DOI: 10.1038/s41598-020-59186-x701077432042028
- 21. Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA targets: From prediction tools to experimental validation. Methods Protoc. 2021;4(1):1-20. DOI: 10.3390/mps4010001783903833374478
- 22. Svec D, Tichopad A, Novosadova V, Pfaffl MW, Kubista M. How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments. Biomol Detect Quantif. 2015;3:9-16. DOI: 10.1016/j.bdq.2015.01.005482221627077029
Language: English
Page range: 261 - 272
Submitted on: Feb 23, 2022
Accepted on: Apr 11, 2022
Published on: Jul 18, 2022
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2022 Onda T. Lupu, Bogdan Popescu, Elena Avram, Mihaela Dragomir, Gheorghe Dănuț Cimponeriu, Ioana Mighiu, Silvia Aposteanu, Daniel Coriu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.